Combating Thermostability with the World’s First Approved Lyophilised mRNA-Based Vaccine
Time: 1:45 pm
day: Day One Track B PM
Details:
- Developing the first self-amplifying mRNA vaccine to gain European approval
- Benchmarking the convenience of 2-8 degrees Celsius storage and supply, pharmacoeconomics and reachability
- Advancing needle free delivery
- Showcasing self-sufficiency of raw materials, ease of manufacturing and stockpiling
